• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs - Real World Outcomes >Economic Burden of Herpes Zoster and Post-Herpetic Neuralgia in Adults 60 Years of Age or Older: Results from a Prospective, Physician Practice-Based Cohort Study in Kushiro, Japan
【24h】

Economic Burden of Herpes Zoster and Post-Herpetic Neuralgia in Adults 60 Years of Age or Older: Results from a Prospective, Physician Practice-Based Cohort Study in Kushiro, Japan

机译：60岁或以上成年人的带状疱疹和疱疹后神经痛的经济负担：来自日本Ku路市的前瞻性，基于医生实践的队列研究结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and ObjectiveHerpes zoster has a high incidence rate among people aged ≥?60 years and can lead to serious complications such as post-herpetic neuralgia. There are currently no data on the economic burden of herpes zoster and post-herpetic neuralgia in Japan, and the objective of this study was to address this gap. MethodsA total of 412 patients aged ≥?60 years diagnosed with herpes zoster were recruited. Demographic, clinical, and healthcare resource utilization data on patients with herpes zoster or post-herpetic neuralgia collected via case report forms were used to estimate direct medical cost. Data obtained from a questionnaire survey among patients with herpes zoster/post-herpetic neuralgia were used to estimate transportation cost and productivity loss. ResultsThe mean number of outpatient visits was 5.7. Prescription medications were the main cost driver accounting for 60% of the direct medical cost. The mean direct medical and total herpes zoster-related costs per patient were ￥43,925 and ￥57,112, respectively, and were higher in patients with post-herpetic neuralgia than in those with herpes zoster without complications. Direct medical cost represented 77%, productivity loss 19%, and transportation cost 4% of the total. ConclusionsThis is the first study of the economic burden of herpes zoster and post-herpetic neuralgia in Japan and it demonstrated substantial direct medical cost as a result of the multiple outpatient visits and prescription medications required. These findings provide baseline data for possible future economic evaluations of new herpes zoster/post-herpetic neuralgia interventions. Trial registrationThis cost analysis is part of a prospective, physician practice-based cohort study conducted between June 2013 and February 2015 in Kushiro, Japan (Clinicaltrials.gov identifier NCT01873365, registered on 6 June, 2013).
机译：背景与目的带状疱疹在≥60岁的人群中发病率很高，并可能导致严重的并发症，例如疱疹后神经痛。日本目前尚无带状疱疹和带状疱疹后神经痛的经济负担数据，本研究的目的是解决这一差距。方法招募412例年龄≥60岁的带状疱疹患者。通过病例报告表收集的带状疱疹或带状疱疹后神经痛患者的人口统计学，临床和医疗保健资源利用数据用于估计直接医疗费用。从带状疱疹/疱疹后神经痛患者的问卷调查中获得的数据用于估计运输成本和生产力损失。结果平均门诊人次为5.7。处方药是主要的成本驱动因素，占直接医疗费用的60％。带状疱疹后神经痛患者的平均直接医疗费用和与带状疱疹有关的总费用分别为￥ 43,925和￥ 57,112，高于无并发症带状疱疹患者。直接医疗费用占总数的77％，生产力损失19％，运输费用占4％。结论这是日本对带状疱疹和带状疱疹后遗神经痛的经济负担的首次研究，它表明由于多次门诊和处方药的使用，直接医疗费用相当可观。这些发现为新带状疱疹/疱疹后神经痛干预措施的未来经济评估提供了基准数据。试验注册该费用分析是2013年6月至2015年2月在日本Ku路市进行的一项基于前瞻性，基于医生实践的队列研究的一部分（Clinicaltrials.gov标识符NCT01873365，于2013年6月6日注册）。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号